Supratentorial Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Supratentorial Cancer

MalaCards integrated aliases for Supratentorial Cancer:

Name: Supratentorial Cancer 12 15
Supratentorial Neoplasms 44 73
Brain Neoplasm, Supratentorial 12
Malignant Supratentorial Tumor 12
Cancer, Supratentorial 73


External Ids:

Disease Ontology 12 DOID:1659
ICD10 33 C71.0
MeSH 44 D015173
NCIt 50 C3397 C4964

Summaries for Supratentorial Cancer

Disease Ontology : 12 A brain cancer that is located in the supratentorial region.

MalaCards based summary : Supratentorial Cancer, also known as supratentorial neoplasms, is related to cerebrum cancer and ureter small cell carcinoma. An important gene associated with Supratentorial Cancer is IER3IP1 (Immediate Early Response 3 Interacting Protein 1), and among its related pathways/superpathways is Neuroscience. The drugs Hydrocortisone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include the supratentorial region, pituitary and brain, and related phenotype is Increased proliferation.

Related Diseases for Supratentorial Cancer

Diseases related to Supratentorial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 184)
# Related Disease Score Top Affiliating Genes
1 cerebrum cancer 27.1 ALX3 ENO2 GFAP IER3IP1 RAD54L RBFOX3
2 ureter small cell carcinoma 10.8 ENO2 SYP
3 malignant sertoli cell tumor 10.8 ENO2 SYP
4 urinary bladder small cell neuroendocrine carcinoma 10.8 ENO2 SYP
5 auditory system cancer 10.8 ENO2 SYP
6 sinonasal undifferentiated carcinoma 10.8 ENO2 SYP
7 sensory organ benign neoplasm 10.8 ENO2 SYP
8 gallbladder small cell carcinoma 10.8 ENO2 SYP
9 pancreatic somatostatinoma 10.8 ENO2 SYP
10 cutaneous ganglioneuroma 10.8 ENO2 SYP
11 extrahepatic bile duct adenocarcinoma 10.8 ENO2 SYP
12 small cell carcinoma of the bladder 10.8 ENO2 SYP
13 papillary tumor of the pineal region 10.8 ENO2 SYP
14 orbital cancer 10.8 ENO2 SYP
15 middle ear adenoma 10.8 ENO2 SYP
16 ovarian carcinosarcoma 10.7 ENO2 SYP
17 desmoplastic infantile ganglioglioma 10.7 GFAP SYP
18 extraventricular neurocytoma 10.7 GFAP SYP
19 pulmonary large cell neuroendocrine carcinoma 10.7 ENO2 SYP
20 lung combined type small cell carcinoma 10.7 GFAP SYP
21 olfactory nerve neoplasm 10.7 ENO2 SYP
22 malignant teratoma 10.7 ENO2 SYP
23 endometrial small cell carcinoma 10.7 ENO2 SYP
24 intracranial cysts 10.7 ENO2 GFAP
25 pilomyxoid astrocytoma 10.7 GFAP SYP
26 nodular ganglioneuroblastoma 10.7 ENO2 SYP
27 chordoid meningioma 10.7 GFAP SYP
28 chiari malformation 10.7 GFAP SYP
29 dysembryoplastic neuroepithelial tumor 10.7 GFAP SYP
30 primitive neuroectodermal tumor of the cervix uteri 10.7 ENO2 GFAP
31 mucinous ovarian cystadenoma 10.7 ENO2 SYP
32 respiratory system benign neoplasm 10.7 ENO2 SYP
33 angiomyoma 10.7 ENO2 SYP
34 gastric squamous cell carcinoma 10.7 ENO2 SYP
35 cerebellar medulloblastoma 10.7 ENO2 GFAP
36 gastric small cell carcinoma 10.7 ENO2 SYP
37 desmoplastic small round cell tumor 10.7 ENO2 SYP
38 angiocentric glioma 10.7 GFAP SYP
39 carcinoid tumors, intestinal 10.7 ENO2 SYP
40 obstructive hydrocephalus 10.7 GFAP SYP
41 bone benign neoplasm 10.7 ENO2 SYP
42 medulloepithelioma 10.7 GFAP SYP
43 cervical clear cell adenocarcinoma 10.7 ENO2 SYP
44 extraskeletal ewing sarcoma 10.7 ENO2 SYP
45 plexiform schwannoma 10.7 ENO2 GFAP
46 frontal convexity meningioma 10.6 GFAP TP53
47 gliofibroma 10.6 GFAP TP53
48 connective tissue benign neoplasm 10.6 ENO2 SYP
49 anaplastic ependymoma 10.6 GFAP SYP
50 cerebral convexity meningioma 10.6 GFAP TP53

Graphical network of the top 20 diseases related to Supratentorial Cancer:

Diseases related to Supratentorial Cancer

Symptoms & Phenotypes for Supratentorial Cancer

GenomeRNAi Phenotypes related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 SMARCB1 TP53

Drugs & Therapeutics for Supratentorial Cancer

Drugs for Supratentorial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 68602 5311068
Menthol Approved Phase 4 2216-51-5 16666
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
Acetaminophen Approved Phase 4 103-90-2 1983
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Ibuprofen Approved Phase 4 15687-27-1 3672
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 83150-76-9 383414 6400441
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 38916-34-6, 51110-01-1 53481605
Dacarbazine Approved, Investigational Phase 4,Phase 2 4342-03-4 5351166
Temozolomide Approved, Investigational Phase 4,Phase 2 85622-93-1 5394
Cefazolin Approved Phase 4 25953-19-9 656510 33255
Cefdinir Approved Phase 4 91832-40-5 6915944
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4,Phase 1 58-05-9 143 6006
Butyric Acid Experimental, Investigational Phase 4,Not Applicable 107-92-6 264
Lactitol Investigational Phase 4 585-86-4 3871
26 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 1,Not Applicable
28 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Cortisol succinate Phase 4,Not Applicable
30 glucocorticoids Phase 4,Phase 1,Not Applicable
31 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Hydrocortisone 17-butyrate 21-propionate Phase 4,Not Applicable
35 Hydrocortisone acetate Phase 4,Not Applicable
36 Hydrocortisone-17-butyrate Phase 4,Not Applicable
37 Analgesics Phase 4,Phase 3,Not Applicable
38 Anesthetics, General Phase 4,Phase 3,Not Applicable
39 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
40 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Not Applicable
41 Hypnotics and Sedatives Phase 4,Phase 3,Phase 1,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Analgesics, Non-Narcotic Phase 4,Not Applicable
44 Adrenergic Agents Phase 4,Not Applicable
45 Adrenergic Agonists Phase 4,Not Applicable
46 Adrenergic alpha-2 Receptor Agonists Phase 4,Not Applicable
47 Adrenergic alpha-Agonists Phase 4,Not Applicable
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
50 Narcotics Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
3 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
4 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
5 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
6 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
7 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
8 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
9 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
10 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Not yet recruiting NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
11 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
12 Anaesthesia for Supratentorial Tumor Resection Completed NCT00389883 Phase 3 Comparison of two anesthetics protocol
13 Cabergoline in Nonfunctioning Pituitary Adenomas Completed NCT03271918 Phase 3 Cabergoline
14 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
15 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
16 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
17 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3 cabergoline
18 Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Not yet recruiting NCT03439709 Phase 3 Lanreotide 60Mg Solution for Injection
19 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Completed NCT01689727 Phase 2 Technetium Tc 99m EC20
20 Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. Completed NCT01283542 Phase 2 Pasireotide LAR
21 Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Completed NCT00001860 Phase 2 Sandostatin LAR Depot versus transsphenoidal surgery
22 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
23 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
24 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
25 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
26 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
27 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
28 Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas Withdrawn NCT01203618 Phase 2 Farletuzumab
29 Temozolomide in Treating Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
30 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
31 HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors Recruiting NCT02457845 Phase 1
32 A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Recruiting NCT03330197 Phase 1 oral veledimex
33 HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Recruiting NCT03500991 Phase 1
34 Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT Recruiting NCT03404414 Phase 1 18F-FDG
35 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Recruiting NCT02769533 Phase 1 OTL0038;Benadryl
36 Intraoperative Imaging of Pituitary Adenomas by OTL Active, not recruiting NCT02629549 Phase 1 OTL38
37 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
38 Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia Unknown status NCT02007798 Not Applicable dexmedetomidine;normal saline
39 Mannitol Brain Relaxation Effect Unknown status NCT02168075 Not Applicable 0.25g/kgof 20% mannitol;0.5g/kg of 20% mannitol;1.0g/kg of 20% mannitol;1.5g/kg of 20% mannitol
40 Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial Unknown status NCT02113358 Not Applicable Intravenous colloid bolus with Voluven
41 Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor Unknown status NCT01476670
42 Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests Unknown status NCT02709863 Not Applicable Sevoflurane;Desflurane;Propofol
43 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
44 Genome-wide Association Study of Pituitary Tumors Unknown status NCT01442220
45 The Predictive Factors of Vision Recovery in Patients With Pituitary Tumor Unknown status NCT01377701
46 The Observational Study of Growth Hormone-secreting Pituitary Tumors Unknown status NCT01368133
47 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501
48 Pituitary Tumor Surveillance: Pathogenic Correlation Unknown status NCT00599092
49 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949
50 A Comparative Study Between Laryngeal Mask Airway and Magensium Sulphate in Attenuating Systemic Stress Response During Emergence of Patients Undergoing Supratentorial Tumours. Completed NCT03406403 Not Applicable Magensium sulphate

Search NIH Clinical Center for Supratentorial Cancer

Cochrane evidence based reviews: supratentorial neoplasms

Genetic Tests for Supratentorial Cancer

Anatomical Context for Supratentorial Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Supratentorial Cancer:

The Supratentorial Region

MalaCards organs/tissues related to Supratentorial Cancer:

Pituitary, Brain, T Cells, Testes, Heart

Publications for Supratentorial Cancer

Variations for Supratentorial Cancer

Expression for Supratentorial Cancer

Search GEO for disease gene expression data for Supratentorial Cancer.

Pathways for Supratentorial Cancer

Pathways related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes

GO Terms for Supratentorial Cancer

Biological processes related to Supratentorial Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 determination of adult lifespan GO:0008340 8.96 RAD54L TP53
2 DNA strand renaturation GO:0000733 8.62 RAD54L TP53

Sources for Supratentorial Cancer

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....